|
|
|
Home
> Anti-aging Research >
Antidepressants & Psychotropics >
Aripiprazole
Abilify (aripiprazole) (Bristol-Myers’ Squibb) (FDA approved
11/02)
Related Topics:
CME:
News & Research:
-
Aripiprazole at Drugstore.com
-
Abilify (aripiprazole) - rxlist.com
- FDA Approves
Aripiprazole to Treat Irritability in Autistic Children - Medscape,
11/24/09
-
Aripiprazole Boosts Efficacy of Antidepressants in Older Patients With Major
Depressive Disorder - Doctor's Guide, 3/9/09
-
Aripiprazole May Prevent Manic Relapse in Bipolar Disorder - Clinical
Psychiatry News, 5/08
-
FDA OKs Abilify for Depression - WebMD, 11/20/07
-
Abilify(R) (Aripiprazole) Approved by U.S. FDA for Add-On Treatment of Major
Depressive Disorder - Doctor's Guide, 11/20/07 - "taking
Abilify plus an ADT provided superior improvement in depressive symptoms to
ADT alone at study endpoint (week six), as measured by the reduction of the
MADRS Total Scores.3 For the secondary endpoint, Abilify plus an ADT was
also superior to placebo plus ADT in reducing the mean SDS Total Score in
one study"
-
FDA OKs Abilify for Teen Schizophrenia - WebMD, 11/6/07
-
Aripiprazole Shows Long-Term Treatment Efficacy in Bipolar Disorder -
Doctor's Guide, 10/15/07
- Aripiprazole
Reverses Antipsychotic-Induced Hyperprolactinemia - Medscape, 10/1/07
-
Aripiprazole Demonstrated Efficacy as Long-Term Maintenance Therapy in
Adults With Bipolar I Disorder Following Treatment for a Recent Manic or
Mixed Episode - Doctor's Guide, 12/8/06
-
Rapidly Disintegrating Oral Antipsychotic Medication Abilify(R) Discmelt(TM)
(Aripiprazole) Launched - Doctor's Guide, 8/17/06
-
Six-Month Study Evaluated Effectiveness of Aripiprazole and Standard of Care
in Management of Community-Treated Patients With Schizophrenia -
Doctor's Guide, 5/31/06
-
Aripiprazole Demonstrated Efficacy as Maintenance Therapy in Adults With
Bipolar I Disorder Following Treatment for a Recent Manic or Mixed Episode
- Doctor's Guide, 5/16/06
-
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Announce Availability
of 2 mg Abilify (Aripiprazole) Tablet and Nonrefrigerated Oral Solution
- Doctor's Guide, 2/8/06
-
Some Developmentally Disabled See Benefits From Aripiprazole - Clinical
Psychiatry News, 11/05
-
Children and Adolescents with Either Bipolar Disorder and Schizophrenia
Respond to Aripiprazole - Doctor's Guide, 10/31/05
-
Aripiprazole Well Tolerated in Pediatric Bipolar Disorder, Schizophrenia
- Medscape, 10/25/05
-
Antipsychotic Drugs: OK for Dementia Patients? - WebMD, 10/18/05
-
Aripiprazole in Schizophrenia: Consensus Guidelines - Medscape, 9/30/05
-
Aripiprazole Wins Out in Comparison With Olanzapine - Clinical
Psychiatry News, 9/05
-
Aripiprazole, Ziprasidone Beneficial and Well Tolerated as Adjuncts in
Bipolar I and II - Doctor's Guide, 6/2/05
-
Intramuscular Aripiprazole Effective at Treating Agitation in Bipolar Mania
- Doctor's Guide, 6/2/05
-
Aripiprazole Gets Broader Approval For Treatment of Bipolar I Disorder -
Clinical Psychiatry News, 4/6/05
-
Abilify (Aripiprazole) Granted Approval for New Indication, Bipolar I
Disorder - Doctor's Guide, 3/7/05
-
Aripiprazole in Bipolar Mania - Clinical Psychiatry News, 3/05
- Aripiprazole Use in
Children and Adolescents - Medscape, 1/25/05
-
FDA Approves Aripiprazole for Acute Bipolar Mania - Clinical Psychiatry
News, 11/04
-
FDA Approves Abilify (Aripiprazole) for Treatment of Acute Bipolar Mania,
Including Manic and Mixed Episodes - Doctor's Guide, 10/4/04
-
New Generation Antipsychotic, Abilify (Aripiprazole), Launched In Europe
- Doctor's Guide, 6/29/04
-
Intramuscular Aripiprazole Provides Rapid and Long-lasting Treatment for
Agitated Psychotic Patients - Doctor's Guide, 5/6/04
- Hyperglycemia,
Diabetes Risks Added to Warning Label of Abilify - Medscape, 4/13/04
- Aripiprazole Reduces
Aggressive Behavior in Children - Medscape, 11/11/03
-
Novel Antipsychotic Agent Aripiprazole Safe, Effective for Treatment of
Schizophrenia and Schizoaffective Disorder - Doctor's Guide, 10/10/03
-
New-Generation Antipsychotic Effective for Treating Mania - Psychiatric
News, 10/3/03
-
Schizophrenia Drug Curbs Bipolar Mania - Clinical Psychiatry News, 9/03
-
FDA Approves Abilify (Aripiprazole) Supplemental New Drug Application for
Maintaining Stability in Patients With Schizophrenia - Doctor's Guide,
9/9/03
- Aripiprazole Safe,
Effective in Schizophrenia, Schizoaffective Disorder - Medscape, 7/18/03
-
Aripiprazole Helps Older Outpatients - Clinical Psychiatry News, 7/03
-
Therapeutic Dose Equivalency Calculation Method Proposed for Atypical
Antipsychotic Medications - Doctor's Guide, 7/16/03 -
"The reported minimum effective doses identified
were 4 mg/day for risperidone, 10 mg/day for olanzapine, 150 mg/day for
quetiapine, 120 mg/day for ziprasidone, 15 mg/day for aripiprazole, and 4
mg/day for haloperidol"
-
Aripiprazole Not Associated with Increased Diabetes Risk - Doctor's
Guide, 5/26/03
-
Aripiprazole Safety Similar in Patients of Various Races - Doctor's
Guide, 5/23/03
-
Novel Antipsychotic's Side Effect Profile Offers Benefits - Clinical
Psychiatry News, 5/03
-
Aripiprazole Benefits Are Sustained Over Time - Clinical Psychiatry
News, 5/03 -
"Its principal advantage over other atypical agents
remains a superior side effect profile; no apparent difference in efficacy
exists ... It's not the new clozapine (Clozaril) ... it seems clearly
superior in areas that have been problematic, notably weight gain, effects
on blood lipids and glucose, and prolactin elevation ... in fact, they lost
weight overall, with the heaviest patients losing most ... Pooled data from
short-term clinical studies showed a mean decline of 57% in serum prolactin"
-
Aripiprazole Effective in Reducing Psychotic Symptoms Associated with
AD-related Dementia - Doctor's Guide, 3/6/03
-
Aripiprazole Wins Approval for Schizophrenia - Clinical Psychiatry News,
1/03
-
FDA Approves New Treatment for Schizophrenia [Abilify™ (aripiprazole)] -
Doctor's Guide, 11/18/02
-
Aripiprazole Efficacious for Acute Mania in Relapsing Bipolar 1 Patients
- Doctor's Guide, 10/9/02
- Aripiprazole Delays
Relapse in Patients with Chronic Schizophrenia - Doctor's Guide, 6/28/02
- Aripiprazole for Long-Term
Maintenance Treatment in Schizophrenia - Doctor's Guide, 5/23/02
-
Meta-Analysis of the Efficacy of Aripiprazole in Schizophrenia -
Doctor's Guide, 5/23/02
-
Aripiprazole Versus Placebo in the Treatment of Chronic Schizophrenia -
Doctor's Guide, 5/23/02
-
Switching to Aripiprazole Safe and Effective in Schizophrenia - Doctor's
Guide, 5/23/02
-
New Antipsychotic Aripiprazole Shows Promise for Acute Mania - Doctor's
Guide, 5/23/02
- Antipsychotic,
Aripiprazole, Continues To Show Efficacy In Schizoaffective Disease, Few
Side Effects - Doctor's Guide, 5/8/01
- Aripiprazole Shows
Promising Efficacy in Schizophrenia - Doctor's Guide, 5/16/00
Abstracts:
-
Changes in metabolic parameters with switching to aripiprazole from another
second-generation antipsychotic: a retrospective chart review - J Clin
Psychiatry. 2007 Mar;68(3):406-9 - "Psychiatric
outpatients switched to aripiprazole from another SGA showed a decrease in
weight, total cholesterol, and LDL. Switching to aripiprazole, when
clinically indicated, may lead to improvement in metabolic parameters
associated with cardiovascular disease"
-
An open trial of aripiprazole augmentation for SSRI non-remitters with
late-life depression - Int J Geriatr Psychiatry. 2007 Mar 6 -
"In this study 50% of depressed patients not
remitting after an adequate trial of an SSRI achieved a final HRSD </= 10
when given aripiprazole augmentation"
-
Aripiprazole augmentation for treatment of patients with inadequate
antidepressants response - Depress Anxiety. 2006 Nov 16
-
Anger,
hostility, and posttraumatic stress disorder in trauma-exposed adults: a
meta-analysis - J Consult Clin Psychol. 2006 Aug;74(4):698-706
-
An open-label, rater-blinded, augmentation study of aripiprazole in
treatment-resistant depression - Prim Care Companion J Clin Psychiatry.
2006;8(2):82-7
-
Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and
Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective
Disorder - Arch Gen Psychiatry. 2003;60:681-690 -
"It is the first non-D2 receptor antagonist with clear antipsychotic effects
and represents a novel treatment development for psychotic disorders"
Related Searches:
70707
|
|
